RIZAMELT

This brand name is authorized in New Zealand.

Active ingredients

The drug RIZAMELT contains one active pharmaceutical ingredient (API):

1
UNII WR978S7QHH - RIZATRIPTAN BENZOATE
 

Rizatriptan binds selectively with high affinity to human 5-HT1B and 5-HT1D receptors. The therapeutic activity of rizatriptan in treating migraine headache may be attributed to its agonist effects at 5-HT1B and 5-HT1D receptors on the extracerebral intracranial blood vessels that are thought to become dilated during an attack and on the trigeminal sensory nerves that innervate them.

 
Read more about Rizatriptan

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
N02CC04 Rizatriptan N Nervous system → N02 Analgesics → N02C Antimigraine preparations → N02CC Selective serotonin (5HT1) agonists
Discover more medicines within N02CC04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
NZ Medicines and Medical Devices Safety Authority 14391

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.